OS Therapies, a Phase 2 biotech developing an off-the-shelf immunotherapy for osteosarcoma, withdrew its filing for an initial public offering on Thursday, before refiling with new terms and underwriters within hours.
The Rockville, MD-based company now plans to raise $8 million by offering 2 million shares at a proposed price of $4. The company had previously filed to offer 2 million shares at a proposed price of $5. At the revised deal size, OS Therapies will raise -20% less in proceeds than previously anticipated and command a market cap of $82 million.
The Rockville, MD-based company was founded in 2018 and plans to list on the NYSE American under the symbol OSTX. Brookline Capital Markets is now the sole bookrunner on the deal.
